Robert Michael Tuttle MD

Dr. Michael Tuttle, an Endocrinologist and Professor of Medicine at Memorial Sloan Kettering Cancer Center in New York, designed and validated the first real-time risk assessment model for thyroid cancer management in which individual risk estimates are modified over time as a function of response to initial therapy. In addition, his clinical studies have helped to define defined the role of recombinant human TSH as an adjuvant for radioactive iodine therapy in both low risk and high-risk patients and in the setting of radioactive iodine avid distant metastases.

His research continues to center on important management aspects of thyroid cancer including efforts to better define the risk of recurrence, the risk of death, and the potential role for observation in low-risk thyroid cancer. His clinical practice is entirely devoted to patients with thyroid cancer with a particular emphasis on cases with aggressive disease and complicated management issues.